Abstract 2792
Background
Patient education is quite a current notion that has proved its efficiency. It has been shown as discussed in previous sections that it improves quite significantly treatment outcomes. Through education and support programs, patients health literacy is improved and so is the adherence of treatment. In this light, an education and support program was adapted at the Mohamed VI center for cancer treatment in Casablanca, with the following objectives: 1. Improve patient’s adherence to treatment 2. Increase early detection of chemotherapy side effects between cures 3. Improve quality of life and avoid toxic deaths.
Methods
In total, 96 patients were included into the program for a period of one year (February 2017- February 2018) and their satisfaction evaluated.
Results
In total, 96 patients were included into the program for a period of one year (February 2017- February 2018) and their satisfaction evaluated. 86,5% of the respondents were female while 13,5% were male. Of this, 70,8 % were literate while 29,2% were illetrate. Most of them, 57,2% had some awareness about cancer before they were included into the program while the rest , 42,8% had no cancer awareness. Most of the patients, 86,5% found that the videos and flyers were easy to understand while 80,2% reported that the same was helpful. 76% of the respondents admitted that the program had helped them become more proactive in their treatment. 78,1% of them were satisfied with the mobile phone calls in managing their complications at home without necessaroly coming to the hospital. 99% of the patients said that they would likely recommend the program to other patients. In overall, 87,5% of the patients were satisfied with the education program while only 3,1 % were dissatisfied. The rest of the respondents, 9,3% were neither satisfied nor dissatisfied.
Conclusions
At the end of the study, our findings were generally comparable to those in the literature and all the indicators were achieved. Therefore, this pilot program should be fully implemented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3190 - GI101, a novel triple-targeting bispecific CD80-IgG4-IL2variant fusion protein, elicits synergistic anti-tumor effects in preclinical models
Presenter: Jae Chan Park
Session: Poster Display session 3
Resources:
Abstract
4062 - Phase 1b, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumors
Presenter: Julius Strauss
Session: Poster Display session 3
Resources:
Abstract
5777 - THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS)
Presenter: Marcos Milla
Session: Poster Display session 3
Resources:
Abstract
5047 - A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells
Presenter: Alessandra Curioni
Session: Poster Display session 3
Resources:
Abstract
1679 - HPV16 E6-specific TCR-T armored with checkpoint blockade in the treatment of cervical cancer
Presenter: Paul Bryson
Session: Poster Display session 3
Resources:
Abstract
1133 - the Mutant Neoantigen Specific T Cell Is a Personalized Immunotherapy in Refractory Solid Tumor
Presenter: Qi Song
Session: Poster Display session 3
Resources:
Abstract
3338 - NY-ESO-1 and LAGE1A –an emerging target for cell therapies in solid tumours
Presenter: Ioanna Eleftheriadou
Session: Poster Display session 3
Resources:
Abstract
3089 - Targeting myeloid-derived suppressor cells and T cells: combination treatment with MTL-CEBPA and PD-1 antibody in a mouse syngeneic CT26 model
Presenter: Mikael Sodergren
Session: Poster Display session 3
Resources:
Abstract
5991 - Master Checkpoint Cbl-b Inhibition: Anti-tumor Efficacy in a Murine Colorectal Cancer Model Following siRNA-based Cell Therapy
Presenter: Kathrin Thell
Session: Poster Display session 3
Resources:
Abstract
5007 - Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
Presenter: Miren Zuazo
Session: Poster Display session 3
Resources:
Abstract